Related Experiment Videos

Somatic genetic analysis of cyclic AMP action: selection of unresponsive mutants

Insights

Dibutyryl cyclic AMP and theophylline induce cell death in lymphoma cells. Mutations conferring resistance suggest a defect in the cyclic AMP binding protein, essential for this cell death pathway.

Area of Science:

  • Cell Biology
  • Molecular Biology
  • Cancer Research

Background:

  • S49.1 mouse lymphoma cells are sensitive to dibutyryl cyclic AMP and theophylline.
  • Cyclic AMP (cAMP) plays a role in cellular regulation and apoptosis.
  • Understanding resistance mechanisms to cAMP-induced cell death is crucial for cancer therapy.

Purpose of the Study:

  • To investigate the mechanism of resistance to cAMP-induced cytolysis in S49.1 mouse lymphoma cells.
  • To determine the mutation rate and genetic basis of resistance.
  • To identify the molecular target affected by the mutation.

Main Methods:

  • Culturing S49.1 cells in soft agar with cytotoxic drugs.
  • Measuring mutation rates to drug resistance.
  • Treating cells with a chemical mutagen (ICR 191) to assess mutagenicity.
  • Analyzing cytoplasmic cyclic AMP binding protein levels in resistant mutants.

Main Results:

  • A low rate of mutation (1-3 x 10^-7/cell/generation) to resistance was observed.
  • Chemical mutagenesis increased the incidence of resistant mutants.
  • Resistant mutants consistently showed reduced or absent cytoplasmic cAMP binding protein.
  • The mutation appears to affect the regulatory subunit of protein kinase.

Conclusions:

  • Somatic mutation leading to a defective cAMP binding protein confers resistance to cAMP-induced cell death.
  • Protein kinase activity is essential for mediating cAMP-induced apoptosis in these cells.
  • This study identifies a specific molecular defect underlying drug resistance in lymphoma cells.

Related Concept Videos